Долгая жизнь с муковисцидозом. Коллектив авторов

Чтение книги онлайн.

СКАЧАТЬ S, Nikolaizik WH, Schoni MH, etal. Differential IgE recognition of recombinant Aspergillus fumigatus allergens by cystic fibrosis patients with allergic bronchopulmonary aspergillosis or Aspergillus allergy. Eur J Immunol 1998; 28: 1155-60.

      181

      Nikolaizik WH,Weichel M, Blaser K, et al. Intracutaneous tests with recombinant allergens in cystic fibrosis patients with allergic bronchopulmonary aspergillosis and Aspergillus allergy. Am J Respir Crit Care Med 2002; 165: 916-21.

      182

      Hemmann S, Nikolaizik WH, Schoni MH, etal. Differential IgE recognition of recombinant Aspergillus fumigatus allergens by cystic fibrosis patients with allergic bronchopulmonary aspergillosis or Aspergillus allergy. Eur J Immunol 1998; 28: 1155-60.

      183

      Fricker-Hidalgo H, Coltey B, Llerena C, et al. Recombinant allergens combined with biological markers in the diagnosis of allergic bronchopulmonary aspergillosis in cystic fibrosis patients. Clin Vaccine Immunol 2010; 17: 1330-6.

      184

      Stevens DA, Moss RB, Kurup VP, et al. Allergic bronchopulmonary aspergillosis in cystic fibrosis-state of the art: Cystic Fibrosis Foundation Consensus Conference. Clin Infect Dis 2003; 37(Suppfl3):S225-64.

      185

      Thomson JM, Wesley A, Byrnes CA, et al. Pulse intravenous methylprednisolone for resistant allergic bronchopulmonary aspergillosis in cystic fibrosis. Pediatr Pulmonol 2006; 41:164-70.

      186

      Thomson JM, Wesley A, Byrnes CA, et al. Pulse intravenous methylprednisolone for resistant allergic bronchopulmonary aspergillosis in cystic fibrosis. Pediatr Pulmonol 2006; 41:164-70.

      187

      Thomas MF, Life-threatening allergic bronchopulmonary aspergillosis treated with methylprednisolone and anti-lgE monoclonal antibody. J R Soc Med 2009; 102(Suppl 1): 49–53.

      188

      Thomas MF, Life-threatening allergic bronchopulmonary aspergillosis treated with methylprednisolone and anti-lgE monoclonal antibody. J R Soc Med 2009; 102(Suppl 1): 49–53.

      189

      Elphick HE, Southern KW. Antifungal therapies for allergic bronchopulmonary aspergillosis in people with cystic fibrosis. Cochrane Database Syst Rev 2012; 6: CD002204.

      190

      Stevens DA, Moss RB, Kurup VP, et al. Allergic bronchopulmonary aspergillosis in cystic fibrosis-state of the art: Cystic Fibrosis Foundation Consensus Conference. Clin Infect Dis 2003; 37(Suppfl3):S225-64.

      191

      Hennig S, Waterhouse TH, Bell SC, et al. A d-optimal designed population pharmacokinetic study of oral itraconazole in adult cystic fibrosis patients. Br J Clin Pharmacol 2007; 63: 438-50.

      192

      Bruggemann RJ, Alffenaar JW, Blijlevens NM, et al. Clinical relevance of the pharmacokinetic interactions of azole antifungal drugs with other coadministered agents. Clin Infect Dis 2009; 48: 1441-58.

      193

      Bruggemann RJ, Alffenaar JW, Blijlevens NM, et al. Clinical relevance of the pharmacokinetic interactions of azole antifungal drugs with other coadministered agents. Clin Infect Dis 2009; 48: 1441-58.

      194

      Tanou K, Zintzaras E, Kaditis AG. Omalizumab therapy for allergic bronchopulmonary aspergillosis in children with cystic fibrosis: a synthesis of published evidence. Pediatr Pulmonol 2014; 49: 503-7.

      195

      Jat KR, Walia DK, Khairwa A. Anti-lgE therapy for allergic bronchopulmonary aspergillosis in people with cystic fibrosis. Cochrane Database Syst Rev 2013; 9:CD010288.

      196

      Ramsey BW. Management of pulmonary disease in patients with cystic fibrosis. New Engl J Med 1996; 335: 179-88.

      197

      Hayes D Jr, Higgins RS, Kirkby S, et al. Impact of pulmonary hypertension on survival in patients with cystic fibrosis undergoing lung transplantation: an analysis of the UNOS registry. J Cyst Fibros 2014; 13: 416-23.

      198

      Toneili AR. Pulmonary hypertension survival effects and treatment options in cystic fibrosis. Curr Opin Pulm Med 2013; 19: 652-61.

      199

      Elphick HE, Mallory G. Oxygen therapy for cystic fibrosis. Cochrane Database Syst Rev 2013; 7: CD003884.

      200

      Elphick HE, Mallory G. Oxygen therapy for cystic fibrosis. Cochrane Database Syst Rev 2013; 7: CD003884.

      201

      Elphick HE, Mallory G. Oxygen therapy for cystic fibrosis. Cochrane Database Syst Rev 2013; 7: CD003884.

      202

      Fauroux B. Why, when and how to propose noninvasive ventilation in cystic fibrosis? Minerva Anesthesio 2011; 77: 1108-14.

      203

      Fauroux B. Why, when and how to propose noninvasive ventilation in cystic fibrosis? Minerva Anesthesio 2011; 77: 1108-14.

      204

      Young AC, Wilson JW, Kotsimbos TC, et al. Randomised placebo controlled trial of non-invasive ventilation for hypercapnia in cystic fibrosis. Thorax 2008; 63: 72-7.

      205

      Fauroux B. Why, when and how to propose noninvasive ventilation in cystic fibrosis? Minerva Anesthesio 2011; 77: 1108-14.

      206

      Flight WG, Shaw J, Johnson S, et al. Long-term non-invasive ventilation in cystic fibrosis – experience over two decades. J Cyst Fibros 2012; 11: 187-92.

      207

      Young AC, Wilson JW, Kotsimbos TC, et al. Randomised placebo controlled trial of non-invasive ventilation for hypercapnia in cystic fibrosis. Thorax 2008; 63: 72-7.

      208

      Mehta S, Hill NS. Noninvasive СКАЧАТЬ